Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
Authors
Rasco, DMiddleton, M
Gonzalez, Rene
Corrie, P
Pavlick, A
Lorigan, Paul C
Plummer, R
Gore, M
Herbert, C
Agarwala, S
Logan, T
Khleif, S
Papadopoulos, K
Rangachari, L
Suri, A
Xu, Q
Kneissl, M
Bozon, V
Olszanski, A
Affiliation
South Texas Accelerated Research Therapeutics START, Oncology,San Antonio, USAIssue Date
2015